Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, Hsu V, Li F, Ricks TK et al (2021) fda approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma FDA approval summary: enfortumab vedotin
Protocol approach: partial rotator cuff tear Goal: Promote tissue healing, prevent tear progression, avoid surgery if possible Peptide approach: BPC-157: 300 to 500 mcg daily, split doses, local injection near shoulder preferred TB-500: 750 to 1000 mcg twice weekly (loading phase first four weeks), then 500 mcg twice weekly GHK-Cu: 300 to 600 mcg daily from week two onward Duration: Twelve weeks minimum Critical notes: Partial tears require imaging to determine severity and location
How much peptide should I inject
Each vial contains 10mg of TB-500 at 99% purity, HPLC-verified by Beyond Health Lab for reproducibility across multi-session protocols